European Journal of Case Reports in Internal Medicine (Oct 2022)

Recurrent Episodes of Hypokalaemia during Treatment with Inhaled Beta-2 Agonist Revealing Gitelman Syndrome, an Uncommon Clinical Entity

  • Nery Sablón-González,
  • Yanet Parodis-Lopez,
  • Maria Belen Alonso-Ortiz,
  • Angélica Laurin,
  • Emmanuel Andres,
  • Noel Lorenzo Villalba

DOI
https://doi.org/10.12890/2022_003605

Abstract

Read online

A 28-year-old female patient was hospitalized for mild–moderate hypokalaemia which was persistent despite discontinuation of beta-2 agonist bronchodilator treatment. Her past medical history was relevant for two episodes of severe hypokalaemia after active inhaled beta-2 agonist treatment for asthma crisis. Investigations revealed increased potassium in spot urine with a transtubular potassium gradient <4. A 24-hour urine analysis showed hypophosphaturia, hypocalciuria, hypomagnesuria and normal urine prostaglandins in favour of Gitelman syndrome. Oral potassium supplementation was started and genetic studies were recommended.

Keywords